

Guido Ahle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2814959/publications.pdf>

Version: 2024-02-01

52
papers

1,700
citations

394421

19
h-index

289244

40
g-index

58
all docs

58
docs citations

58
times ranked

3201
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1079.	9.0	357
2	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. <i>Neuro-Oncology</i> , 2016, 18, 1297-1303.	1.2	135
3	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. <i>Haematologica</i> , 2018, 103, 1278-1287.	3.5	129
4	Management and outcome of primary CNS lymphoma in the modern era. <i>Neurology</i> , 2020, 94, e1027-e1039.	1.1	125
5	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). <i>European Journal of Cancer</i> , 2020, 141, 62-81.	2.8	122
6	Familial occurrence of tardive dyskinesia. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 375-379.	4.5	79
7	The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. <i>European Journal of Cancer</i> , 2016, 61, 69-76.	2.8	66
8	Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. <i>American Journal of Medical Genetics Part A</i> , 2001, 105, 498-501.	2.4	56
9	CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1027-1038.	1.9	51
10	Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. <i>Journal of Neuro-Oncology</i> , 2017, 133, 315-320.	2.9	47
11	Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria. <i>Acta Neurologica Scandinavica</i> , 2004, 109, 385-389.	2.1	44
12	Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 43.	5.2	44
13	Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma. <i>Neuro-Oncology</i> , 2016, 18, 361-367.	1.2	42
14	Vitreous microRNA levels as diagnostic biomarkers for vitreoretinal lymphoma. <i>Blood</i> , 2017, 129, 3130-3133.	1.4	33
15	Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab. <i>Emerging Infectious Diseases</i> , 2018, 24, 1594-1596.	4.3	33
16	MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS. <i>Journal of Neuro-Oncology</i> , 2018, 137, 463-468.	2.9	26
17	Familial occurrence of tardive dyskinesia. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 375-379.	4.5	25
18	Fulminant tumefactive multiple sclerosis: Therapeutic implications of histopathology. <i>Journal of Neurology</i> , 2008, 255, 1272-1273.	3.6	22

#	ARTICLE	IF	CITATIONS
19	Transcranial magnetic stimulation as a provocation for epileptic seizures in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 475-476.	3.0	21
20	Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An <sc>LOC</sc> network study. <i>American Journal of Hematology</i> , 2021, 96, 823-833.	4.1	18
21	First Results of the AcsÃ© Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort. <i>Blood</i> , 2020, 136, 15-16.	1.4	18
22	Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103188.	4.4	17
23	Optic Nerve Infiltration in Primary Central Nervous System Lymphoma. <i>JAMA Neurology</i> , 2017, 74, 1368.	9.0	16
24	Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma. <i>Neurology</i> , 2021, 97, 628-631.	1.1	16
25	Cytomorphology and flow cytometry of brain biopsy rinse fluid enables faster and multidisciplinary diagnosis of large B-cell lymphoma of the central nervous system. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 182-188.	1.5	15
26	Shape changes in prefrontal, but not parieto-occipital regions: brains of schizophrenic patients come closer to a circle in coronal and sagittal view. <i>Psychiatry Research - Neuroimaging</i> , 2004, 132, 261-271.	1.8	14
27	A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study. <i>Neuro-Oncology</i> , 2019, 21, 1039-1048.	1.2	13
28	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life experience of the French Network. <i>Bone Marrow Transplantation</i> , 2022, 57, 966-974.	2.4	12
29	Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2016, 20, 282-291.	1.4	11
30	Late-onset riboflavin transporter deficiency: a treatable mimic of various motor neuropathy aetiologies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 27-35.	1.9	11
31	Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study. <i>Journal of Neuro-Oncology</i> , 2019, 144, 419-426.	2.9	10
32	Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML. <i>European Radiology</i> , 2021, 31, 2944-2955.	4.5	10
33	Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. <i>Journal of Neurology</i> , 2019, 266, 1743-1755.	3.6	9
34	Complementary and alternative medicine use in glioma patients in France. <i>Journal of Neuro-Oncology</i> , 2019, 145, 487-499.	2.9	8
35	Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. <i>Revue Neurologique</i> , 2018, 174, 675-679.	1.5	7
36	(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study. <i>Annals of Hematology</i> , 2019, 98, 915-922.	1.8	7

#	ARTICLE	IF	CITATIONS
37	CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma. <i>Journal of Neurology</i> , 2021, 268, 2890-2894.	3.6	4
38	Successful treatment of hyperventilation-induced nystagmus in vestibular schwannoma with oxcarbazepine. <i>Journal of Neurology</i> , 2008, 255, 1093-1093.	3.6	3
39	Chemotherapy is an efficient treatment in primary CNS MALT lymphoma. <i>Journal of Neuro-Oncology</i> , 2022, 159, 151-161.	2.9	3
40	Acute left hemispheric syndrome with cortical lesions in a patient with secondary porphyria. <i>Journal of Neurology</i> , 2005, 252, 983-984.	3.6	2
41	P14.118 Carboxypeptidase G2 (CPC2) rescue after high dose methotrexate (hdMTX) chemotherapy for Primary CNS Lymphoma (PCNSL). A French LOC network study. <i>Neuro-Oncology</i> , 2019, 21, iii96-iii96.	1.2	2
42	The French LOC Network for Primary CNS Lymphoma (PCNSL) Patients: What Can We Learn from a Large National Database?. <i>Blood</i> , 2016, 128, 926-926.	1.4	2
43	Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study. <i>Hematological Oncology</i> , 2022, 40, 976-986.	1.7	2
44	Primary lymphomatoid granulomatosis in the central nervous system: A report of three cases. <i>Neuropathology</i> , 2019, 39, 168-169.	1.2	1
45	Intravascular Large B-Cell Lymphoma Presenting as Dementia and Hemolytic Anemia. <i>Onkologie</i> , 2010, 33, 174-177.	0.8	0
46	Superficial Siderosis, Traumatic Tap, and Xanthochromia. <i>Archives of Neurology</i> , 2012, 69, 791; author reply 791-2.	4.5	0
47	Une embœche de l'artère vertébrale. <i>Pratique Neurologique - FMC</i> , 2017, 8, 191-194.	0.1	0
48	P14.49 Primary central nervous system lymphoma presenting as dementia: do not forget IL10 in CSF analysis. <i>Neuro-Oncology</i> , 2019, 21, iii78-iii78.	1.2	0
49	P14.87 Leptomeningeal dissemination in high grade glioma: Correlation of MRI, cytology and standard CSF indices. <i>Neuro-Oncology</i> , 2019, 21, iii88-iii88.	1.2	0
50	OS1.3 Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. <i>Neuro-Oncology</i> , 2019, 21, iii5-iii6.	1.2	0
51	P14.90 Interleukin 6 is a useful marker for pseudotumoral inflammatory CNS lesions suspicious of lymphoma. <i>Neuro-Oncology</i> , 2019, 21, iii89-iii89.	1.2	0
52	P13.13 Clinical factors involved in brain metastasis edema: results of a retrospective cohort and evaluation of the best edema descriptor. <i>Neuro-Oncology</i> , 2019, 21, iii65-iii65.	1.2	0